➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Moodys
Express Scripts
Mallinckrodt
Johnson and Johnson

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ponesimod

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Ponesimod?

Ponesimod is an investigational drug.

There have been 8 clinical trials for Ponesimod. The most recent clinical trial was a Phase 1 trial, which was initiated on July 13th 2017.

The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Graft vs Host Disease. The leading clinical trial sponsors are Actelion, Janssen Pharmaceutica N.V., Belgium, and [disabled in preview].

There are twenty-eight US patents protecting this investigational drug and two hundred and sixty-three international patents.

Recent Clinical Trials for Ponesimod
TitleSponsorPhase
A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady StateJanssen Pharmaceutica N.V., BelgiumPhase 1
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisActelionPhase 3
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)ActelionPhase 3

See all Ponesimod clinical trials

Clinical Trial Summary for Ponesimod

Top disease conditions for Ponesimod
Top clinical trial sponsors for Ponesimod

See all Ponesimod clinical trials

US Patents for Ponesimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ponesimod   Get Started for $10 WT1 peptide cancer vaccine composition for transdermal administration NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP)   Get Started for $10
Ponesimod   Get Started for $10 Vaccine composition NITTO DENKO CORPORATION (Osaka, JP)   Get Started for $10
Ponesimod   Get Started for $10 Stabilization of alcohol intoxication-induced cardiovascular instability UNIVERSITY OF SOUTH FLORIDA (Tampa, FL)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ponesimod

Drugname Country Document Number Estimated Expiration Related US Patent
Ponesimod Canada CA2840941 2033-02-05   Get Started for $10
Ponesimod China CN103961699 2033-02-05   Get Started for $10
Ponesimod European Patent Office EP2762152 2033-02-05   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Merck
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.